• Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

    25 days ago - By Fierce Biotech

    Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3 ntaylor
    Mon, 02/08/2021 - 07:35
    Read more ...